<DOC>
	<DOCNO>NCT02928133</DOCNO>
	<brief_summary>Rationale : Adult patient congenital heart disease ( CHD ) atrial tachyarrhythmias need anticoagulated . It know whether non-vitamin K antagonist oral anticoagulant ( NOAC ) patient group efficient safe . Aim : The purpose NOTE registry evaluate efficacy safety NOACs thromboembolic prevention atrial tachyarrhythmias adult patient congenital heart disease ( CHD ) . Methods : In multicenter prospective registry adult CHD patient atrial tachyarrhythmias NOACs ( switch VKA new anticoagulant ) follow minimum two year . Primary efficacy endpoint define thromboembolism , i.e . composite ischemic stroke , systemic pulmonary embolism intracardiac thrombosis , composite stroke systemic embolism . Primary safety endpoint define major bleed accord ISTH criterion . Secondary endpoint include thromboembolic bleeding event analyse separately , all-cause mortality , therapy adherence , quality life , risk assessment stroke evaluation natural history atrial tachyarrhythmia adult CHD patient . Primary endpoint assessment perform per protocol analysis , demonstrate Kaplan Meyer estimate event free survival event rate per year .</brief_summary>
	<brief_title>NOACs Atrial Tachyarrhythmias Congenital Heart Disease</brief_title>
	<detailed_description>Rationale : Adult patient congenital heart disease ( CHD ) atrial tachyarrhythmias need anticoagulated . It know whether non-vitamin K antagonist oral anticoagulant ( NOAC ) patient group efficient safe . Aim : The purpose NOTE registry evaluate efficacy safety NOACs thromboembolic prevention atrial tachyarrhythmia 's adult patient CHD . Methods : In multicenter prospective registry adult CHD patient atrial tachyarrhythmia 's NOACs follow period two year . Patient population : Registry population consist CHD patient tachyarrhythmia 's , define atrial fibrillation ( AF ) atrial tachycardia 's ( AT ) , include atrial flutter , NOACs . Patients new-onset atrial tachyarrhythmia 's eligible NOACs , start directly NOAC . Patients vitamin K antagonist ( VKA ) switch actively NOACs outpatient clinic visit , case agreement patient physician . The switch initiate various reason , include bleed complication VKA , unstable INR measurement , user friendliness . Eligibility NOAC use define conform clinical practice , i.e . patient nonvalvular atrial tachyarrhythmia 's , without mechanical heart valve , significantly elevate risk bleeding , impaired renal function , pregnancy . Registration process : Patients include registry start NOAC treatment . Exclusion criterion expect survival less two year additional indication anticoagulation besides atrial tachyarrhythmia 's . At baseline general patient characteristic register . Standard echocardiography laboratory assessment follow-up adult CHD patient record registration period . Quality life therapy adherence assess questionnaire . Registry follow-up warrant telephone contact outpatient clinic visit . At follow-up point occurrence pre-defined event record . A detailed description variable use registry provide protocol . Anonymized data collect investigational site enter central database main investigational site ( Academic Medical Center , Amsterdam , The Netherlands ) . Quality assurance : At investigational site investigator train registry protocol , case report form registry procedures prior enrol subject . The assigned monitoring investigator main site , assure regular site monitoring audit investigational site . Source data verify compare data medical record case report form form random sample . To avoid minimize bias , independent clinical event committee main investigational site , consist independent physician , ass primary endpoint clinical event . Intermediate evaluation take place one year enrollment last patient consist verification record data , assessment accuracy patient follow-up primary endpoint analysis . Drop-outs : Patients quite NOACs lose follow-up consider drop-outs . Those ( temporarily ) quite NOACs follow total follow-up 2 year complete . The event occur period off-NOAC include analysis . A clear description reason NOAC arrest interruption possible alternative anticoagulant therapy assess . Endpoints : Primary efficacy endpoint define thromboembolism , i.e . composite ischemic stroke , systemic pulmonary embolism intracardiac thrombosis , composite stroke systemic embolism . Primary safety endpoint define major bleed accord ISTH criterion . Secondary endpoint include thromboembolic bleeding event analyze separately , all-cause mortality , therapy adherence , quality life , risk assessment stroke evaluation natural history atrial tachyarrhythmia adult CHD patient . Sample size : By use estimate event rate describe patient population ( thromboembolism event rate 1.4 % per year , mainly VKA ; unpublished data ) relative risk reduction 0.81 stroke systemic embolism NOACs compare VKA [ Ruff et al , Lancet 2013 ] , sample size 300 patient follow two year necessary demonstrate safety NOACs thromboembolic prevention safety margin 2.7 % thromboembolic event per year . Statistical analysis : Endpoint assessment perform per protocol analysis , demonstrate Kaplan Meyer ( KM ) estimate event free survival event rate per year . The result compare KM estimate event rate historical similar cohort VKA non-inferiority assay . Drop-outs ( see ) censor time drop-out time-to-event analysis , include event-rate analysis time drop-out . No adjustment imputation miss data perform available data present .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Heart Defects , Congenital</mesh_term>
	<mesh_term>Tachycardia , Ectopic Atrial</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Atrial tachyarrhythmia Congenital heart disease Treatment NOAC expect survival less two year additional indication anticoagulation besides atrial tachyarrhythmia 's</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non-vitamin K antagonist oral anticoagulant ( NOAC )</keyword>
	<keyword>Congenital heart disease</keyword>
	<keyword>Atrial fibrillation</keyword>
	<keyword>Atrial tachyarrhythmia</keyword>
	<keyword>Thromboembolism</keyword>
</DOC>